2026-06-14T00:32:08Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/227032024-11-29T01:27:30Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Pavord, Ian
author
Bahmer, Thomas
author
Braido, Fulvio
author
García-Cosío, Borja
author
Humbert, Marc
author
Idzko, Marco
author
Adamek, Lukasz
2024-09-10T13:08:54Z
2024-09-10T13:08:54Z
2019-06-30
Pavord I, Bahmer T, Braido F, Cosio BG, Humbert M, Idzko M, et al. Severe T2-high asthma in the biologics era: European experts' opinion. Eur Respir Rev. 2019 Jun 30;28(152):190054.
10.1183/16000617.0054-2019
1600-0617
0905-9180
European Respiratory Review
http://hdl.handle.net/20.500.13003/17440
31285291
L2002404964
2-s2.0-85069307012
https://hdl.handle.net/20.500.12105/22703
477993000004
The European Respiratory Biologics Forum gathered participants from 21 countries in Madrid, Spain, to discuss the management and treatment of severe asthma in the era of biologics. The current insights on the pathophysiology of severe asthma were discussed, as well as the role of respiratory biologics in clinical practice and strategies for eliminating chronic use of oral corticosteroids. The participants also highlighted the key challenges in identifying patients with severe asthma based on phenotypes, biomarkers and treatable traits, and the existing problems in patient referral to specialist care. The monitoring of treatment was debated and the need for a change towards precision medicine and personalised care was emphasised throughout the meeting. This review provides a summary of the discussions and highlights important concerns identified by the participants regarding the current management of severe asthma.
eng
Severe T2-high asthma in the biologics era: European experts' opinion
review article